Compare Merck & Co., Inc. (MRK) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Transocean Ltd — how do they compare? Merck & Co., Inc. trades at $142.38 (market cap $352.29B), while Transocean Ltd trades at $5.54 (market cap $6.02B). The key difference: Merck & Co., Inc. is far larger — about 58.5× Transocean Ltd's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Transocean Ltd for 18 Days on average.
| MRK | RIG | |
|---|---|---|
Market Cap | $352.29B | $6.02B |
Volume | 6,348,796 | 19,180,005 |
Sector | Health | Energy |
52-Week High | $156.43 | $7.58 |
52-Week Low | $82.49 | $3.08 |
Typical Hold Time | 98 Days | 18 Days |
Enterprise Value | $399.05B | $10.63B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
